AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Lexaria Bioscience Corp. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SBJ1Q1
3.08▲ 0.09 (3.01%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
2.99
Day's Range
2.84 – 3.20
52-Week Range
0.35 – 14.37
Volume
23.2K
Avg Volume
72.5K
Share Statistics
Shares Outstanding
Employees
7
Exchange
XNAS
Listed
2006-09-08
Share count as of July 13, 2026

Lexaria Bioscience Corp. Common Stock (LEXX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Lexaria Bioscience Corp. Common Stock (LEXX)
What is Lexaria Bioscience Corp. Common Stock's Market Cap?
Lexaria Bioscience Corp. Common Stock's Market Cap is $76.3M, based on as-reported figures from SEC (XBRL) filings.
What is Lexaria Bioscience Corp. Common Stock's Price / Sales?
Lexaria Bioscience Corp. Common Stock's Price / Sales is 393.5×, based on as-reported figures from SEC (XBRL) filings.
What is Lexaria Bioscience Corp. Common Stock's Revenue (TTM)?
Lexaria Bioscience Corp. Common Stock's Revenue (TTM) is $194.0K, based on as-reported figures from SEC (XBRL) filings.
What is Lexaria Bioscience Corp. Common Stock's Net Income (TTM)?
Lexaria Bioscience Corp. Common Stock's Net Income (TTM) is -$7.7M, based on as-reported figures from SEC (XBRL) filings.
What is Lexaria Bioscience Corp. Common Stock's EBITDA?
Lexaria Bioscience Corp. Common Stock's EBITDA is -$7.7M, based on as-reported figures from SEC (XBRL) filings.
What is Lexaria Bioscience Corp. Common Stock's Diluted EPS (TTM)?
Lexaria Bioscience Corp. Common Stock's Diluted EPS (TTM) is -0.31, based on as-reported figures from SEC (XBRL) filings.
What is Lexaria Bioscience Corp. Common Stock's EBITDA Margin?
Lexaria Bioscience Corp. Common Stock's EBITDA Margin is -3946.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · LEXXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemMay 31, 2026Feb 28, 2026Nov 30, 2025Aug 31, 2025May 31, 2025Feb 28, 2025Nov 30, 2024Aug 31, 2024May 31, 2024Feb 29, 2024Nov 30, 2023Aug 31, 2023May 31, 2023Feb 28, 2023Nov 30, 2022Aug 31, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)
Revenues——
YoY growth-100.0%——+107.1%
Cost of Revenue——
Gross profit——
% of revenue———100.0%
Operating expenses
Research and Development Expense——
Selling, General and Administrative Expense——
Total operating expenses——
% of revenue———1645.2%
Loss from operations——
% of revenue———-1545.2%
Other income (loss)
Interest Income——
Non-Operating Income (Expense)——
Total other income (loss)——
Net loss before income taxes———
Net loss——
% of revenue———-1550.1%
Net Income Attributable to Noncontrolling Interest
Net loss attributable to Lexaria shareholders
% of revenue———-1549.3%
Earnings Per Share (Diluted)——